EyeBio is formerly owned by Jeito Capital, through Jeito I, since 2022.

When did Jeito Capital acquire EyeBio?

Jeito Capital acquired EyeBio in 2022 and exited after 2 years.

Has EyeBio been sold?

Yes. EyeBio was exited in 2024 via Trade Sale.

Home/Companies/Biotech/EyeBio

EyeBio

Biotech·

US·Exited 2024·Held 2yr

EyeBio is a healthcare company, headquartered in France.

Entry

2022

Hold

2yr

Exit

2024

Est. EV

–

Investor

Jeito Capital

Key facts

HQFrance

SectorHealthcare

Wilmington and London-based ophthalmology biotech (Eyebiotech) developing Restoret for diabetic macular edema; Jeito Capital backed 2022…Read full notes

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Exit details: type, year, MOIC (buyer on Pro)

Start free

Already a member? Sign in

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals

More PE-backed in Biotech

Comparable biotech deals from other GPs.

AdBio PartnersBelgium

Last updated April 2026 · Sourced from public filings